Composition, form of production and packaging
? Tablets from white with a yellowish shade of color to white with a creamy shade of color, are allowed inclusions, with a risk and a facet.
1 tab.
chondroitin sodium sulfate 250 mg
Excipients: calcium stearate monohydrate (calcium stearate 1-water) 4.8 mg, crospovidone (polyplasdone XL-10, collidon CL-M) 12.39 mg, povidone K30 (collidone 30) 9.312 mg, microcrystalline cellulose 96 mg, magnesium hydroxycarbonate pentahydrate (magnesium carbonate basic water) - 107.498 mg.
10 pieces. - packings cellular planimetric (3) - packs cardboard.
10 pieces. - packings cellular planimetric (5) - packs cardboard.
10 pieces. - packings cellular planimetric (6) - packs cardboard.
10 pieces. - packings cellular planimetric (9) - packs cardboard.
10 pieces. - packings cellular planimetric (10) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2012.
PHARMACHOLOGIC EFFECT
A drug that regulates metabolism in cartilage tissue. Has chondro-stimulating, regenerating and anti-inflammatory action.
Chondroxide В® participates in the construction of the main substance of cartilage and bone tissue. Affects the exchange processes in the hyaline and fibrous cartilage. It inhibits degenerative processes in the cartilaginous and connective tissue, inhibits enzymes that cause damage to the cartilaginous tissue.
Chondroxide В® stimulates the biosynthesis of proteoglycans, promotes the regeneration of the articular bag and the cartilaginous surfaces of the joints, increases the production of intraarticular fluid, and has anti-inflammatory effect. Slows the resorption of bone tissue and reduces calcium loss, accelerates the recovery of bone tissue.
Chondroxide В® slows the progression of osteoarthritis and osteochondrosis. When using the drug, soreness decreases and mobility of affected joints improves, while the therapeutic effect persists for a long time after the end of the course of therapy.
PHARMACOKINETICS
With a single admission of a median therapeutic dose, T max in plasma is 3-4 hours, T max in synovial fluid is 4-5 hours. Bioavailability is 13%.
Accumulated mainly in the cartilaginous tissue (T max in articular cartilage is 48 h): the synovial membrane is not an obstacle for the penetration of the drug into the joint cavity. It is excreted by the kidneys within 24 hours.
INDICATIONS
Degenerative and dystrophic diseases of the joints and spine:
- treatment and prevention of osteoarthritis, osteochondrosis of the spine.
DOSING MODE
The drug should be taken orally by 500 mg (2 tablets) 2 times / day, washed down with a small amount of water.
The recommended duration of the initial course of treatment is 6 months.
The therapeutic effect of the drug persists for 3-5 months after its withdrawal, depending on the location and stage of the disease. If necessary, it is possible to conduct repeated courses of treatment, the duration of which is determined individually.
SIDE EFFECT
In some cases: allergic reactions, nausea, diarrhea.
CONTRAINDICATIONS
- Pregnancy;
- lactation period;
- Hypersensitivity to the components of the drug.
With caution , use the drug for bleeding or with a tendency to bleeding.
PREGNANCY AND LACTATION
Contraindicated use of the drug during pregnancy and lactation.
APPLICATION FOR CHILDREN
The efficacy and safety of chondroitin sulfate in children have not been established.
SPECIAL INSTRUCTIONS
When combined with indirect anticoagulants, antiplatelet agents, fibrinolytic drugs, more frequent control of blood coagulation is required.
Use in Pediatrics
The efficacy and safety of chondroitin sulfate in children have not been established.
Impact on the ability to drive vehicles and manage mechanisms
Does not affect the ability to manage vehicles and other mechanisms.
OVERDOSE
Symptoms : rarely - nausea, vomiting, diarrhea, with prolonged use in excessively high doses (more than 3 g / day), hemorrhagic rashes are possible.
Treatment: symptomatic therapy.
DRUG INTERACTION
It is possible to increase the effect of indirect anticoagulants, antiplatelet agents, fibrinolytic agents.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, dry, protected from light at a temperature of no higher than 25 В° C. Shelf life - 2 years.
